Summary
Probucol is known to prolong QT intervals in some patients and to produce fatal arrhythmias in selected animal species. To assess the prevalence and clinical relevance of this effect in a controlled manner, we analyzed electrocardiograms (ECGs) and medical events in patients during a placebo-controlled crossover trial comparing single or combined administration of probucol and colestipol. Forty-two Type II hyperlipoproteinemic patients were studied for eighteen to twenty-four months. Two cardiologists independently read the tracings which were previously arranged randomly without names or dates. There were no statistical differences between the reports of the ECG parameters by the two cardiologists. The mean QTc interval of the entire patient population was lengthened after probucol administration without reaching statistical significance when compared to placebos or colestipol treatments. Forty-eight % of the patients showed lengthening of the QTc interval during probucol treatment by 11 to 70 msec increment over baseline placebo. The remaining had either no change or shortening of the interval. There were no statistically significant differences in means of R-R, PR, QRS, QTc or QoT intervals among placebo, probucol., colestipol and probucol plus colestipol treatments. It is concluded that probucol prolonged QT intervals in the electrocardiograms of about one half of patients receiving the drug with no other clinical or statistically significant evidence of cardiotoxicity or electrocardiographic effects.
Similar content being viewed by others
References
Troendle G, Gueriguian J, Sobel S, Johnson M (1982) Probucol and the QT interval. Lancet 1: 1179
National Heart, Lung and Blood Institute (1980) Diet 2. For dietary management of hypercholesterolemia (Type IIa hyperlipoporteinemia). DHEW publication No. (NIH) 80–112
Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20: 470–475
Bucolo G and David H (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19: 476–482
Grove TH (1979) Effect of reagent pH on determination of high-density lipoprotein cholesterol by precipitation with sodium phosphotungstatemagnesium. Clin Chem 25: 450–454
Havel RJ, Eder HA and Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345–1353
Dujovne, CA, Hurwitz A, Kauffman RE, Azarnoff DL (1974) Colestipol and clofibrate in hypercholesterolemia. Clin Pharm Therap 16: 291–296
Dujovne CA, Krehbiel P, DeCoursey S, Jackson B, Chernoff S, Pitterman A, Garty M (1984) Probucol plus colestipol in treatment of hypercholesterolemia. Ann Intern Med 100: 411–482
Marshall FN, Lewis JE (1973) Sensitization to epinephrine-induced ventricular fibrillation produced by probucol in dogs. Toxicol Appl Pharmacol 24: 594–602
Miettinen TA, Huttunen JK, Kuusi T, Kumlin T, Mattila S, Naukkarinen V, Strandberg T (1982) Clinical experience with probucol with special emphasis on mode of action and long-term treatment. Artery 10: 35–43
McCaughan D (1981) Long-term effects of probucol on serum lipid levels. Arch Intern Med 141: 1428–1432
Molello JA, Gerbig CG, Robinson VB (1973) Toxicity of [4,4′-(isopropylidene-dithio)bis(2,6-di-t-butylphenol)], probucol, in mice, rats, dogs and monkeys: demonstration of a species-specific phenomenon. Toxicol Appl Pharmacol 24: 590–593
Bachman S, Sparrow D, Smith LK (1981) Effect of aging on the electrocardiogram. Am J Cardiol 48: 513–516
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dujovne, C.A., Atkins, F., Wong, B. et al. Electrocardiographic effects of probucol. A controlled prospective clinical trial. Eur J Clin Pharmacol 26, 735–739 (1984). https://doi.org/10.1007/BF00541934
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00541934